Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 47

    1.

    Modeling sequence evolution in acute HIV-1 infection.

    Lee HY, Giorgi EE, Keele BF, Gaschen B, Athreya GS, Salazar-Gonzalez JF, Pham KT, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Hahn BH, Shaw GM, Korber BT, Bhattacharya T, Perelson AS.

    J Theor Biol. 2009 Nov 21;261(2):341-60. Epub 2009 Aug 4.PMID: 19660475 [PubMed - in process]Related articles

    2.

    Gender differences in discontinuation of antiretroviral treatment regimens.

    Kempf MC, Pisu M, Dumcheva A, Westfall AO, Kilby JM, Saag MS.

    J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):336-41.PMID: 19654551 [PubMed - indexed for MEDLINE]Related articles

    3.

    Retroviruses and other latent viruses: the deadliest of pathogens are not necessarily the best candidates for bioterrorism.

    Salgado CD, Kilby JM.

    J S C Med Assoc. 2009 Jun;105(3):104-6.PMID: 19639767 [PubMed - indexed for MEDLINE]Related articles

    4.

    Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.

    Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM.

    Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7. Epub 2008 May 19.PMID: 18490657 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline.

    Kilby JM, Lee HY, Hazelwood JD, Bansal A, Bucy RP, Saag MS, Shaw GM, Acosta EP, Johnson VA, Perelson AS, Goepfert PA; UAB Acute Infection, Early Disease Research Program (AIEDRP) Group.

    AIDS. 2008 May 11;22(8):957-62.PMID: 18453855 [PubMed - indexed for MEDLINE]Related articles

    6.

    The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.

    Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reichman R, Erice A, Bucy RP, Kilby JM, Lederman MM, Hamilton CD, Lertora J, White BL, Tebas P, Duliege AM, Pollard RB; AIDS Clinical Trials Group 328 Study Team.

    Arch Intern Med. 2007 Mar 26;167(6):597-605.PMID: 17389292 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Functionally competent antigen-specific CD127(hi) memory CD8+ T cells are preserved only in HIV-infected individuals receiving early treatment.

    Sabbaj S, Heath SL, Bansal A, Vohra S, Kilby JM, Zajac AJ, Goepfert PA.

    J Infect Dis. 2007 Jan 1;195(1):108-17. Epub 2006 Nov 20.PMID: 17152014 [PubMed - indexed for MEDLINE]Related articles

    8.

    A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).

    Kilby JM, Bucy RP, Mildvan D, Fischl M, Santana-Bagur J, Lennox J, Pilcher C, Zolopa A, Lawrence J, Pollard RB, Habib RE, Sahner D, Fox L, Aga E, Bosch RJ, Mitsuyasu R; Adult AIDS Clinical Trials Group A5024 Protocol Team.

    J Infect Dis. 2006 Dec 15;194(12):1672-6. Epub 2006 Nov 8.PMID: 17109338 [PubMed - indexed for MEDLINE]Related articles

    9.

    A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.

    Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, Kilby JM, Daar E, Conway B, Holte S; AIEDRP Network.

    J Infect Dis. 2006 Sep 15;194(6):725-33. Epub 2006 Aug 15.PMID: 16941337 [PubMed - indexed for MEDLINE]Related articles

    10.

    Delayed access to HIV diagnosis and care: Special concerns for the Southern United States.

    Krawczyk CS, Funkhouser E, Kilby JM, Vermund SH.

    AIDS Care. 2006;18 Suppl 1:S35-44.PMID: 16938673 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Factors associated with delayed initiation of HIV medical care among infected persons attending a southern HIV/AIDS clinic.

    Krawczyk CS, Funkhouser E, Kilby JM, Kaslow RA, Bey AK, Vermund SH.

    South Med J. 2006 May;99(5):472-81.PMID: 16711309 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States.

    Hornberger J, Kilby JM, Wintfeld N, Green J.

    AIDS Res Hum Retroviruses. 2006 Mar;22(3):240-7.PMID: 16545010 [PubMed - indexed for MEDLINE]Related articles

    13.

    Therapeutic immunization strategies for HIV infection.

    Heath SL, Kilby JM.

    Curr Opin HIV AIDS. 2006 Jan;1(1):74-81.PMID: 19372788 [PubMed - in process]Related articles

    14.

    Salmonella infections in the setting of AIDS: a serpentine course.

    Kilby JM.

    South Med J. 2005 Nov;98(11):1066-7. No abstract available. PMID: 16351025 [PubMed - indexed for MEDLINE]Related articles

    15.

    Therapeutic potential of blocking HIV entry into cells: focus on membrane fusion inhibitors.

    Kilby JM.

    Expert Opin Investig Drugs. 1999 Aug;8(8):1157-70.PMID: 15992142 [PubMed]Related articles

    16.

    Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection.

    Betts MR, Exley B, Price DA, Bansal A, Camacho ZT, Teaberry V, West SM, Ambrozak DR, Tomaras G, Roederer M, Kilby JM, Tartaglia J, Belshe R, Gao F, Douek DC, Weinhold KJ, Koup RA, Goepfert P, Ferrari G.

    Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4512-7. Epub 2005 Mar 7.PMID: 15753288 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides.

    Bansal A, Gough E, Sabbaj S, Ritter D, Yusim K, Sfakianos G, Aldrovandi G, Kaslow RA, Wilson CM, Mulligan MJ, Kilby JM, Goepfert PA.

    AIDS. 2005 Feb 18;19(3):241-50.PMID: 15718834 [PubMed - indexed for MEDLINE]Related articles

    18.

    Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.

    Wheeler DA, Lalezari JP, Kilby JM, Wheat J, Delehanty J, DeMasi R, Patel I, Salgo M.

    J Clin Virol. 2004 Jun;30(2):183-90.PMID: 15125875 [PubMed - indexed for MEDLINE]Related articles

    19.

    Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.

    Eron JJ, Gulick RM, Bartlett JA, Merigan T, Arduino R, Kilby JM, Yangco B, Diers A, Drobnes C, DeMasi R, Greenberg M, Melby T, Raskino C, Rusnak P, Zhang Y, Spence R, Miralles GD.

    J Infect Dis. 2004 Mar 15;189(6):1075-83. Epub 2004 Mar 2.PMID: 14999611 [PubMed - indexed for MEDLINE]Related articles

    20.

    Novel therapies based on mechanisms of HIV-1 cell entry.

    Kilby JM, Eron JJ.

    N Engl J Med. 2003 May 29;348(22):2228-38. Review. No abstract available. PMID: 12773651 [PubMed - indexed for MEDLINE]Related articles

    21.

    Antibody neutralization and escape by HIV-1.

    Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM.

    Nature. 2003 Mar 20;422(6929):307-12.PMID: 12646921 [PubMed - indexed for MEDLINE]Related articles

    22.

    A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.

    Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL, Sista PR, Dusek A, Kilby JM.

    AIDS. 2003 Mar 28;17(5):691-8.PMID: 12646792 [PubMed - indexed for MEDLINE]Related articles

    23.

    Enfuvirtide.

    Chen RY, Kilby JM, Saag MS.

    Expert Opin Investig Drugs. 2002 Dec;11(12):1837-43. Review.PMID: 12457443 [PubMed - indexed for MEDLINE]Related articles

    24.

    The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

    Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, Goodgame JC, Gallant JE, Volberding P, Murphy RL, Valentine F, Saag MS, Nelson EL, Sista PR, Dusek A.

    AIDS Res Hum Retroviruses. 2002 Jul 1;18(10):685-93. Erratum in: AIDS Res Hum Retroviruses. 2003 Jan 1;19(1):83.. PMID: 12167274 [PubMed - indexed for MEDLINE]Related articles

    25.

    Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

    Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC.

    Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905.PMID: 12019106 [PubMed - indexed for MEDLINE]Related articlesFree article

    27.

    SIVcpz in wild chimpanzees.

    Santiago ML, Rodenburg CM, Kamenya S, Bibollet-Ruche F, Gao F, Bailes E, Meleth S, Soong SJ, Kilby JM, Moldoveanu Z, Fahey B, Muller MN, Ayouba A, Nerrienet E, McClure HM, Heeney JL, Pusey AE, Collins DA, Boesch C, Wrangham RW, Goodall J, Sharp PM, Shaw GM, Hahn BH.

    Science. 2002 Jan 18;295(5554):465. No abstract available. PMID: 11799233 [PubMed - indexed for MEDLINE]Related articlesFree article

    28.

    Human immunodeficiency virus pathogenesis: insights from studies of lymphoid cells and tissues.

    Kilby JM.

    Clin Infect Dis. 2001 Sep 15;33(6):873-84. Epub 2001 Aug 6. Review.PMID: 11512093 [PubMed - indexed for MEDLINE]Related articles

    29.

    Perspectives on inducing efficient immune control of HIV-1 replication--a new goal for HIV therapeutics?

    Bucy RP, Kilby JM.

    AIDS. 2001 Feb;15 Suppl 2:S36-42. Review.PMID: 11424975 [PubMed - indexed for MEDLINE]Related articles

    30.

    Prolonged suppression of human immunodeficiency virus type 1 RNA during dual nucleoside reverse-transcriptase-inhibitor therapy in clinical practice.

    Hoesley CJ, Saag MS, Chatham A, Kilby JM.

    Clin Infect Dis. 2000 Oct;31(4):1095-7.PMID: 11049795 [PubMed - indexed for MEDLINE]Related articles

    31.

    Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report.

    Kilby JM, Goepfert PA, Miller AP, Gnann JW Jr, Sillers M, Saag MS, Bucy RP.

    Ann Intern Med. 2000 Sep 19;133(6):435-8. Review.PMID: 10975961 [PubMed - indexed for MEDLINE]Related articlesFree article

    32.

    Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults.

    Kilby JM, Sfakianos G, Gizzi N, Siemon-Hryczyk P, Ehrensing E, Oo C, Buss N, Saag MS.

    Antimicrob Agents Chemother. 2000 Oct;44(10):2672-8.PMID: 10991842 [PubMed - indexed for MEDLINE]Related articlesFree article

    33.

    Stability in the HIV vDNA pool in peripheral CD4+ T cells of untreated patients by single tube quantitative PCR.

    Hockett RD Jr, Saag MS, Kilby JM, Sfakianos G, Wakefield TB, Bucy RP.

    J Virol Methods. 2000 Jun;87(1-2):1-12.PMID: 10856747 [PubMed - indexed for MEDLINE]Related articles

    35.

    Images in clinical medicine. Cytomegalovirus esophageal ulcers.

    Kilby JM, Singh S.

    N Engl J Med. 2000 Feb 17;342(7):475. No abstract available. PMID: 10675428 [PubMed - indexed for MEDLINE]Related articles

    36.

    Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy.

    Derdeyn CA, Kilby JM, Miralles GD, Li LF, Sfakianos G, Saag MS, Hockett RD, Bucy RP.

    J Infect Dis. 1999 Dec;180(6):1851-62.PMID: 10558941 [PubMed - indexed for MEDLINE]Related articles

    37.

    Correlation between circulating stromal cell-derived factor 1 levels and CD4+ cell count in human immunodeficiency virus type 1-infected individuals.

    Derdeyn CA, Costello C, Kilby JM, Sfakianos G, Saag MS, Kaslow R, Bucy RP.

    AIDS Res Hum Retroviruses. 1999 Aug 10;15(12):1063-71.PMID: 10461826 [PubMed - indexed for MEDLINE]Related articles

    38.

    HIV-1 and HAART: a time to cure, a time to kill.

    Saag MS, Kilby JM.

    Nat Med. 1999 Jun;5(6):609-11. No abstract available. PMID: 10371490 [PubMed - indexed for MEDLINE]Related articles

    39.

    Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA.

    Hockett RD, Kilby JM, Derdeyn CA, Saag MS, Sillers M, Squires K, Chiz S, Nowak MA, Shaw GM, Bucy RP.

    J Exp Med. 1999 May 17;189(10):1545-54.PMID: 10330433 [PubMed - indexed for MEDLINE]Related articlesFree article

    40.

    Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues.

    Bucy RP, Hockett RD, Derdeyn CA, Saag MS, Squires K, Sillers M, Mitsuyasu RT, Kilby JM.

    J Clin Invest. 1999 May 15;103(10):1391-8.PMID: 10330421 [PubMed - indexed for MEDLINE]Related articlesFree article

    41.

    Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.

    Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS.

    Nat Med. 1998 Nov;4(11):1302-7.PMID: 9809555 [PubMed - indexed for MEDLINE]Related articles

    42.

    The yield of bone marrow biopsy and culture compared with blood culture in the evaluation of HIV-infected patients for mycobacterial and fungal infections.

    Kilby JM, Marques MB, Jaye DL, Tabereaux PB, Reddy VB, Waites KB.

    Am J Med. 1998 Feb;104(2):123-8.PMID: 9528729 [PubMed - indexed for MEDLINE]Related articles

    43.

    Severe hyperglycemia in an HIV clinic: preexisting versus drug-associated diabetes mellitus.

    Kilby JM, Tabereaux PB.

    J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jan 1;17(1):46-50.PMID: 9436758 [PubMed - indexed for MEDLINE]Related articles

    44.

    Effects of tapering doses of oral prednisone on viral load among HIV-infected patients with unexplained weight loss.

    Kilby JM, Tabereaux PB, Mulanovich V, Shaw GM, Bucy RP, Saag MS.

    AIDS Res Hum Retroviruses. 1997 Nov 20;13(17):1533-7.PMID: 9390753 [PubMed - indexed for MEDLINE]Related articles

    45.

    Clinical experience with non-nucleoside reverse transcriptase inhibitors: L-697,661 and nevirapine.

    Kilby JM, Saag MS.

    Adv Exp Med Biol. 1996;394:291-8. Review. No abstract available. PMID: 8815693 [PubMed - indexed for MEDLINE]Related articles

    46.

    Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection?

    Kilby JM, Saag MS.

    Infect Agents Dis. 1994 Dec;3(6):313-23. Review.PMID: 7534192 [PubMed - indexed for MEDLINE]Related articles

    47.

    Nontuberculous mycobacteria in adult patients with cystic fibrosis.

    Kilby JM, Gilligan PH, Yankaskas JR, Highsmith WE Jr, Edwards LJ, Knowles MR.

    Chest. 1992 Jul;102(1):70-5.PMID: 1623799 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Find related data

    Search details

    » See more...